Young RM, Shaffer III, AL, Phelan JD, Staudt LM. B-cell receptor signaling in diffuse large B-Cell lymphoma. Semin Hematol. 2015;52:77–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Young RM, Phelan JD, Wilson WH, Staudt LM. Pathogenic B-cell receptor signaling in lymphoid malignancies: new insights to improve treatment. Immunol Rev. 2019;291:190–213.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood. 2009;114:2467–75.

Article  CAS  PubMed  Google Scholar 

Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Melani C, Lakhotia R, Pittaluga S, Phelan JD, Huang DW, Wright G, et al. Combination targeted therapy in relapsed diffuse large B-Cell Lymphoma. N. Engl J Med. 2024;390:2143–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Newsam AD, Coughlin CA, Trabolsi A, Schatz JH. Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphoma. Leuk Lymphoma. 2023;0:1–8.

Google Scholar 

Trabolsi A, Arumov A, Schatz JH. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J. 2024;14:1–10.

Article  Google Scholar 

Xia M, David L, Teater M, Gutierrez J, Wang X, Meydan C, et al. BCL10 mutations define distinct dependencies guiding precision therapy for DLBCL. Cancer Discov. 2022;12:1922–41.

CAS  PubMed  PubMed Central  Google Scholar 

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N. Engl J Med. 2018;378:1396–407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM. et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y. et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39:1643–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uehata T, Iwasaki H, Vandenbon A, Matsushita K, Hernandez-Cuellar E, Kuniyoshi K, et al. Malt1-Induced Cleavage of Regnase-1 in CD4+ Helper T Cells Regulates Immune Activation. Cell. 2013;153:1036–49.

Article  CAS  PubMed  Google Scholar 

Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, et al. B-cell receptor driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood. 2017;129:333–46.

Keenan AB, Torre D, Lachmann A, Leong AK, Wojciechowicz ML, Utti V, et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 2019;47:W212–W224.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 2013;14:128.

Article  Google Scholar 

Gambini E, Martinelli I, Stadiotti I, Vinci MC, Scopece A, Eramo L, et al. Differences in mitochondrial membrane potential identify distinct populations of human cardiac mesenchymal progenitor cells. Int J Mol Sci. 2020;21:7467.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peters TL, Tillotson J, Yeomans AM, Wilmore S, Lemm E, Jiménez-Romero C, et al. Target-based screening against eIF4A1 reveals the marine natural product Elatol as a novel inhibitor of translation initiation with in vivo antitumor activity. Clin Cancer Res. 2018;24:4256–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loo LSW, Soetedjo AAP, Lau HH, Ng NHJ, Ghosh S, Nguyen L, et al. BCL-xL/BCL2L1 is a critical anti-apoptotic protein that promotes the survival of differentiating pancreatic cells from human pluripotent stem cells. Cell Death Dis. 2020;11:378.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hiraki M, Maeda T, Mehrotra N, Jin C, Alam M, Bouillez A, et al. Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer. Signal Transduct Target Ther. 2018;3:13.

Article  PubMed  PubMed Central  Google Scholar 

Eltobgy MM, Zani A, Kenney AD, Estfanous S, Kim E, Badr A, et al. Caspase-4/11 exacerbates disease severity in SARS–CoV-2 infection by promoting inflammation and immunothrombosis. Proc Natl Acad Sci USA. 2022;119:e2202012119.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illés Á, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137:600–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Binder JX, Pletscher-Frankild S, Tsafou K, Stolte C, O’Donoghue SI, Schneider R, et al. Compartments: unification and visualization of protein subcellular localization evidence. Database. 2014;2014:bau012–bau012.

Article  PubMed  PubMed Central  Google Scholar 

Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A. et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171:481–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111:3701–13.

Hatzi K, Geng H, Doane AS, Meydan C, LaRiviere R, Cardenas M, et al. Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. Nat Immunol. 2019;20:86–96.

Article  CAS  PubMed  Google Scholar 

Tkacik E, Li K, Gonzalez-Del Pino G, Ha BH, Vinals J, Park E, et al. Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. J Biol Chem. 2023;299:104634.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Molica S. Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia. Int J Hematol Oncol. 2020;9:IJH31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Von Keudell G, Moskowitz AJ. The role of PI3K inhibition in lymphoid malignancies. Curr Hematol Malig Rep. 2019;14:405–13.

Article  Google Scholar 

Seshadri MR, Melnick AM. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. Leuk Lymphoma. 2021;0:1–10.

Google Scholar 

Fontan L, Goldstein R, Casalena G, Durant M, Teater MR, Wilson J, et al. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. Blood. 2021;137:788–800.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Juilland M, Thome M. Holding all the CARDs: how MALT1 controls CARMA/CARD-Dependent signaling. Front Immunol. 2018;9. https://doi.org/10.3389/fimmu.2018.01927.